Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Average (2016 - 2025)

Historic Equity Average for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $509.1 million.

  • Viridian Therapeutics, Inc.\DE's Equity Average fell 1768.18% to $509.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $509.1 million, marking a year-over-year decrease of 1768.18%. This contributed to the annual value of $556.8 million for FY2024, which is 3304.02% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Equity Average stood at $509.1 million, which was down 1768.18% from $559.8 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Equity Average registered a high of $689.6 million during Q4 2024, and its lowest value of $102.5 million during Q2 2021.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Equity Average had a median value of $362.8 million in 2023 and averaged $369.7 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Equity Average soared by 61897.99% in 2021, and later plummeted by 1768.18% in 2025.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Equity Average stood at $196.2 million in 2021, then soared by 104.96% to $402.0 million in 2022, then dropped by 9.76% to $362.8 million in 2023, then skyrocketed by 90.07% to $689.6 million in 2024, then dropped by 26.18% to $509.1 million in 2025.
  • Its Equity Average stands at $509.1 million for Q3 2025, versus $559.8 million for Q2 2025 and $638.1 million for Q1 2025.